Justin Gainor

Citada per

	Totes	Des de 2020
Citacions	43788	29262
Índex h	88	79
Índex i10	227	208

7000

3500

1750

5250

20122013201420152016201720182019202020212022202320242025207 281 517 976 2049 2767 3220 3841 5090 6450 5985 5660 5243 662

Accés públic

Mostra-ho tot

131 articles

7 articles

disponibles

no disponibles

Es basa en els requisits de les agències que proporcionen el finançament

Coautors

subba digumarthyMassachusetts General HospitalCorreu electrònic verificat a partners.org
Aaron HataMassachusetts General Hospital, Harvard Medical SchoolCorreu electrònic verificat a mgh.harvard.edu
Vivek Subbiah, MDAssociate Professor, The University of Texas MD Anderson Cancer CenterCorreu electrònic verificat a mdanderson.org
Lecia V SequistProfessor of Medicine, Harvard Medical School and Massachusetts General HospitalCorreu electrònic verificat a partners.org
Matthew HellmannMemorial Sloan Kettering Cancer CenterCorreu electrònic verificat a mskcc.org
Joe LennerzMassachusetts General Hospital/Harvard Medical SchoolCorreu electrònic verificat a partners.org
luc fribouletGustave Roussy Université Paris SaclayCorreu electrònic verificat a gustaveroussy.fr
Sai-Hong Ignatius OuUniversity of California IrvineCorreu electrònic verificat a uci.edu
Ryan SullivanMassachusetts General HospitalCorreu electrònic verificat a mgh.harvard.edu
Scott J AntoniaCorreu electrònic verificat a duke.edu
Benjamin SolomonMedical Oncologist, Peter MacCallum Cancer CentreCorreu electrònic verificat a petermac.org
Ryohei KatayamaJapanese Foundation for Cancer ResearchCorreu electrònic verificat a jfcr.or.jp
Robert C. Doebele, MD, PhDUniversity of Colorado, Anschutz Medical CampusCorreu electrònic verificat a cuanschutz.edu
Gregory J. Riely, MD, PhDMemorial Sloan Kettering Cancer CenterCorreu electrònic verificat a MSKCC.org
Wilfried EberhardtInnere Klinik (Tumorforschung), University of Duisburg-EssenCorreu electrònic verificat a uni-duisburg-essen.de
Paul BaasDepartment of Thoracic Oncology, Netherlands Cancer InstituteCorreu electrònic verificat a nki.nl
Stephen V. LiuGeorgetown UniversityCorreu electrònic verificat a gunet.georgetown.edu
Michael LanutiAssociate Professor of Surgery, Harvard Medical SchoolCorreu electrònic verificat a partners.org
Daniel SW TanNational Cancer Centre SingaporeCorreu electrònic verificat a nccs.com.sg
Alexander DrilonMemorial Sloan Kettering Cancer CenterCorreu electrònic verificat a mskcc.org

Segueix

Justin Gainor

Director, Center for Thoracic Cancers Program, Massachusetts General Hospital

Correu electrònic verificat a partners.org

Lung cancer targeted therapy thoracic oncology immunotherapy


Títol Ordena per cites Ordena per any Ordena per títol	Citada per Citada per	Any
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015	9279	2015
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020	1958	2020
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018	1393	2018
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633-641, 2018	1324	2018
EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ... Clinical cancer research 22 (18), 4585-4593, 2016	1206	2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016	1191	2016
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011	1154	2011
The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ... Cancer discovery 4 (6), 662-673, 2014	940	2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014	823	2014
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020	786	2020
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial AT Shaw, E Felip, TM Bauer, B Besse, A Navarro, S Postel-Vinay, ... The Lancet Oncology 18 (12), 1590-1599, 2017	708	2017
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ... Clinical cancer research 19 (15), 4273-4281, 2013	673	2013
First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, ... Journal of Clinical Oncology 37 (12), 992-1000, 2019	576	2019
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial CA Shu, JF Gainor, MM Awad, C Chiuzan, CM Grigg, A Pabani, ... The Lancet Oncology 21 (6), 786-795, 2020	559	2020
Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F AT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ... New England Journal of Medicine 374 (1), 54-61, 2016	545	2016
PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li, M West, RW Tang, ... Cancer cell 28 (1), 70-81, 2015	502	2015
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ... Annals of oncology 29 (4), 959-965, 2018	490	2018
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ... Annals of Oncology 22 (12), 2616-2624, 2011	478	2011
Acquired resistance to crizotinib from a mutation in CD74–ROS1 MM Awad, R Katayama, M McTigue, W Liu, YL Deng, A Brooun, ... New England Journal of Medicine 368 (25), 2395-2401, 2013	475	2013
A combinatorial strategy for treating KRAS-mutant lung cancer E Manchado, S Weissmueller, JP Morris, CC Chen, R Wullenkord, ... Nature 534 (7609), 647-651, 2016	440	2016

En aquests moments el sistema no pot dur a terme l'operació. Torneu-ho a provar més tard.

Articles 1–20

Cites per any

Cites duplicades

Cites combinades

Addició de coautorsCoautors

Segueix

Citada per

Coautors